Cipla Stock Update: Share Price Rises Over 2% on Citi Bullish Call
Cipla (NSE: CIPLA) share price is trading at ₹1,446.30, up 2.16% intraday, as a Citi 'Buy' rating and catalyst watch boosts investor sentiment on US growth and regulatory triggers.
Cipla shares are witnessing a robust upswing in intraday trade, currently trading at INR 1,446.30, marking a significant gain of 2.16% from its previous close of INR 1,415.70. The pharmaceutical major opened the session higher at INR 1,422.80, demonstrating early buying interest, and has since climbed to an intraday high of INR 1,447.00, pushing past its intraday low of INR 1,418.80. Volume for the session stands at 1,046,889 shares, indicating active participation as investors respond to fresh positive sentiment surrounding the stock.
| CIPLA – Stock Updates as of (10:13AM, 23 Jun 2026) | |||
|
LTP
₹1,446.30 |
Open
₹1,422.80 |
High
₹1,447.00 |
Low
₹1,418.80 |
|
52W High
₹0.00 |
52W Low
₹0.00 |
Volume
1,046,889 |
% Chg
+2.16% |
52-Week Context
The current surge places Cipla notably above its 52-week low of INR 1,165.55 recorded on April 2, 2026. The stock touched its 52-week high of INR 1,672 on October 23, 2025, suggesting that while today's move is strong, the stock still has considerable ground to cover to re-test its annual peak. This upward momentum, however, positions Cipla well within its annual trading range, hinting at a potential recovery from recent dips.
Latest Developments
The primary catalyst driving Cipla's strong performance today stems from a renewed bullish outlook by a major international brokerage. Citi reiterated a 'Buy' rating on the stock on Monday, June 22, 2026, and placed it on a 90-day Positive Catalyst Watch, signaling expectations for identifiable near-term triggers to move the stock. This positive stance follows a period of weakness for Cipla, with the brokerage now believing that the worst for the company's earnings may be behind it, especially after the impact from gRevlimid-related pressures.
Citi's optimism is anchored in several key developments. The brokerage highlights upcoming US product catalysts, including the anticipated approval of gFlovent from Cipla's Goa facility and the expected launch of gVentolin, which are set to strengthen the company's US portfolio and support revenue recovery in the American market. Furthermore, Cipla's India formulations business continues to provide a strong anchor, contributing nearly two-thirds of its EBITDA, with sustained strength in domestic demand and a recovery in its respiratory portfolio.
A significant regulatory trigger to watch is the potential positive outcome from the USFDA re-inspection of Cipla's Indore facility, which is currently under Official Action Indicated (OAI). A favorable resolution could unlock additional product approvals and improve US pipeline visibility, acting as a major sentiment booster for the stock. Citi has also set a target price of INR 1,700 for Cipla, implying a potential upside of approximately 25-26% from recent levels. Adding to the positive news, Cipla recently elevated Saurabh Gambhir to Chief Strategy Officer (Global) on June 22, 2026, to drive enterprise growth and strategic expansion.
Investors will closely monitor further updates on the USFDA's decision regarding the Indore plant and the timelines for key generic product launches in the US. Sustained buying interest, particularly on strong volumes, could indicate continued positive momentum for Cipla throughout the trading session.
Disclaimer: The information provided in this article is based on news reports and is not intended as investment advice. Investing in stocks involves risk. LatestLY advises its readers to consult with a financial advisor before making any investment decisions.
(The above story first appeared on LatestLY on Jun 23, 2026 10:13 AM IST. For more news and updates on politics, world, sports, entertainment and lifestyle, log on to our website latestly.com).